Berobenatide

GLP-1 agonist (long-acting) · Pfizer

Top dose

9.6 mg monthly

Weight loss

-12.3%

at week 28 · treatment regimen

AE discontinuation

9.3%

Status

phase 2

Pivotal trial #

Trial: VESPER-3
Indication: obesity
Duration: 28 weeks
Sponsor: Pfizer

Notes #

Placebo-corrected -12.3% at week 28 (on-treatment, 4.8 mg QM, VESPER-3 Arm 3). ae_disc not directly comparable: the ADA 2026 deck (Mallory et al, conference-only) gives no clean per-dose AE-led discontinuation - only 9.3% (20/215) pooled across ALL VESPER-3 berobenatide groups (includes escalation/high-dose arms, like MariTide), plus a separate 0% for the Ph3 maintenance-dose arms (2.4 QW / 3.2 QM / 4.8 QM, N=108) from the VESPER-1 open-label extension (a switch population). GI-specific 8.4%. Ph3 program: VESPER-4/-5 (weekly, PCD 2H 2027) + VESPER-6 (monthly, PCD 2Q 2028) + switch / OSA / knee OA. Target first approval 2028. Berobenatide = PF-08653944 (not PF-07976016). No CTgov results posted for any PF-08653944 trial as of Jun 2026; VESPER-3's CTgov record not cleanly identifiable, so nct_id/ctgov_url left null (the previous NCT06717438 was wrong - an unrelated Jordan's Syndrome trial).